Lindbrook Capital, LLC Zai Lab LTD Transaction History

Lindbrook Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 21, 2022	SELL	$27.77 - $64.4 $13,968 - $32,393	-503 Closed	0 $0
Q4 2021 Jan 18, 2022	BUY	$54.9 - $105.21 $10,156 - $19,463	185 Added 58.18%	503 $32,000
Q3 2021 Nov 05, 2021	BUY	$105.0 - $178.37 $945 - $1,605	9 Added 2.91%	318 $34,000
Q2 2021 Jul 27, 2021	BUY	$125.11 - $180.0 $4,754 - $6,840	38 Added 14.02%	309 $55,000
Q1 2021 Apr 28, 2021	BUY	$126.27 - $191.71 $1,515 - $2,300	12 Added 4.63%	271 $36,000
Q4 2020 Jan 27, 2021	BUY	$81.94 - $135.34 $6,473 - $10,691	79 Added 43.89%	259 $35,000
Q3 2020 Nov 03, 2020	SELL	$73.3 - $89.48 $2,565 - $3,131	-35 Reduced 16.28%	180 $15,000
Q2 2020 Jul 27, 2020	BUY	$48.82 - $82.53 $2,636 - $4,456	54 Added 33.54%	215 $18,000
Q1 2020 Apr 22, 2020	BUY	$39.1 - $62.9 $508 - $817	13 Added 8.78%	161 $8,000
Q1 2019 Apr 23, 2019	BUY	$21.71 - $31.54 $3,213 - $4,667	148 New	148 $4,000

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.66B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.